KEYNOTE-177
2020
Pembrolizumab in MSI-H/dMMR Metastatic Colorectal Cancer
In 307 patients with untreated MSI-H/dMMR metastatic colorectal cancer, pembrolizumab improved progression-free survival compared with chemotherapy ± targeted agents.
Result
Efficacy: Progression-free survivalHR 0.6
Below 1 favours pembrolizumab, above 1 favours chemotherapy ± targeted agents.
Event rates Pembrolizumab 16.5 vs chemotherapy ± targeted agents 8.2 months
Also reported: No OS benefit at primary readout (heavy crossover).
- Subtopic
- MSI-H mCRC
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- André T, et al. N Engl J Med. 2020;383(23):2207-2218.doi 10.1056/NEJMoa2017699
Discussion & critique
Established checkpoint inhibition as first-line standard in MSI-H/dMMR mCRC. Universal MMR/MSI testing at diagnosis is now non-negotiable.